Navigating Asia-Pacific Innovation Deal Opportunities

As several new therapies originating in China begin reaching the review and regulatory approval phases for patients around the world, it is clearer than ever that R&D and innovation from the region can produce valuable partnerships and investment opportunities.  This enthusiasm of Cross-Pacific dealmakers and investors wanting to support biopharma development as well as the maturation of APAC biopharma companies adds new facets to typical business development relationships.  Join this panel to hear from experts on recent deals and learn about the opportunities and pitfalls when considering cross-Pacific collaboration looking forward.